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Association with Genetic Variants in the IL-23 and
NF-κB Pathways Discriminates between Mild and
Severe Psoriasis Skin Disease
Pernilla Nikamo1, Joseﬁn Lysell1 and Mona Ståhle1
Psoriasis is clinically heterogeneous, and symptoms can vary from mild almost cosmetic symptoms to severe
disease requiring systemic therapy. Biomarkers predicting disease development are lacking. Herein we explored
the genetic background in two polarized cohorts of carefully phenotyped patients with long-term follow-up:
consistent mild phenotype (n= 696) and severe disease course requiring systemic therapy (n= 715). All patients
were treated at the same dermatology department ensuring homogenous assessment. Genotyping included
known psoriasis-associated variants, with special focus on the IL-23 and NF-κB pathways. A case–case study
comparing severe and mild psoriasis phenotypes, controlling for age at disease onset and gender, revealed
signiﬁcant differences between the two groups for SNPs in IL23R, NFKB1, IL21, IL12B, NFKBIL1 and IL23A.
HLA-C*06 associated equally in the mild and severe disease cohorts. Strong additive effects when combining
HLA-C*06 with IL23A, IL23R, IL12B, NFKB1 or TNIP1 were restricted to the severe cohort, indicating that activation
of these pathways may inﬂuence disease severity in psoriasis. No protective gene was identiﬁed in the mild
cohort, suggesting that current screens have primarily identiﬁed psoriasis variants associated with a more severe
phenotype. These results demonstrate the importance of careful phenotyping and long-term clinical follow-up in
genetic studies.
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INTRODUCTION
Psoriasis is a common inﬂammatory skin disease with a
complex genetic background (Nair et al., 2009; Nestle et al.,
2009; Strange et al., 2010), and it affects 2–3% of the Caucasian
population (Nestle et al., 2009). The aim of this study was to
compare proﬁles of known psoriasis-associated genetic variants
between patients with a severe and mild disease course
focusing on the skin phenotype. How to deﬁne disease severity
is not trivial even when only considering skin involvement, but
the psoriasis area severity index (PASI) is commonly used for
grading (Fredriksson and Pettersson, 1978). Obviously, PASI is a
subjective measure, and scores will vary over time in the
individual patient and most importantly will reﬂect ongoing
treatments. A more functional approach was applied in the
present study. The disease was considered severe when
requiring systemic therapy and mild when only topical or no
treatment was applied/indicated. All patients were examined
and treated at the same department with long-term follow-up
ensuring a reasonable consistency in assessment.
The genetic contribution to disease is extensive with HLA-
C*06 showing the most signiﬁcant association (Nair et al.,
2000), although genome-wide association studies have
identiﬁed another 35 psoriasis risk regions presented at
ImmunoBase (http://www.immunobase.org/). The majority of
susceptibility genes are involved in the immune system and in
pathways that clearly have a role in the pathophysiology of
psoriasis. Thus, drugs targeting these pathways show impressive
efﬁcacy in controlling psoriasis inﬂammation, and their in vivo
relevance has convincingly been validated (Cargill et al., 2007;
de Cid et al., 2009; Ellinghaus et al., 2010; Huffmeier et al.,
2010; Strange et al., 2010; Tsoi et al., 2012). Psoriasis
inﬂammation arises through combined innate and adaptive
immune responses (Dempsey et al., 2003), and in this process
T cells are important factors regulating the cross-talk between
the immune system and the skin (Nair et al., 2009). In recent
years, researchers have focused on the pathological IL23/IL17/
IL22 axis, where data from genetic, experimental, and clinical
research seem to converge (Di Cesare et al., 2009).
IL-23 has a crucial role in the development of pathogenic
Th17 cells and induces inﬂammation (Aggarwal et al., 2003;
Bettelli et al., 2006). Other genes that also have a role in the
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psoriasis-associated IL-23 signaling pathway are IL21, STAT3,
and TYK2 (Andres et al., 2013; Caruso et al., 2009b;
Ellinghaus et al., 2012), and, it has been shown that IL21
and STAT3 are upregulated in psoriasis lesions (Andres et al.,
2013; Caruso et al., 2009b), whereas Tyk2 is downregulated
(Andres et al., 2013). IL-13 is produced mainly by Th2 cells
and has been associated with psoriasis arthritis (PsA) (Eder
et al., 2011), and IL-21 is produced by Th17 cells and has
shown association with psoriasis (Yin et al., 2014).
Nuclear factor-kappa B (NF-κB)/Rel transcription factors
have a critical role in regulating the expression of many
cytokines involved in the pathogenesis of psoriasis (Baeuerle
and Baltimore, 1996; Baldwin, 1996; Barnes and Karin,
1997). NF-κB is composed of homo- or heterodimers of Rel
and NF-κB proteins (Baeuerle and Baltimore, 1996). NF-κB
complexes are held in the cytoplasm in an inactive state
bound to members of the NF-κB inhibitor (NFKBI) family such
as NFKBIA and NFKBIL1. Tumor necrosis factor alpha (TNFA)
is a multifunctional proinﬂammatory cytokine that stimulates
NF-κB activity. Other proteins involved in regulating NF-κB
activation are TNFA-induced protein 3 (TNFAIP3), TNFAIP3-
interacting protein 1 (TNIP1), and TRAF3-interacting protein 2
(TRAF3IP2). Dysregulation of the NF-κB system is thought to
be central in inﬂammatory and stress responses.
Psoriasis shows large clinical variation, but few studies
have explored the genetic proﬁles, apart from HLA-C*06, in
stratiﬁed phenotypes (Fan et al., 2007; Zheng et al., 2010;
Julià et al., 2012; Lysell et al., 2013). With the exception for
generalized pustular psoriasis (Marrakchi et al., 2011;
Onoufriadis et al., 2011), most genetic studies have
analyzed a mixture of clinical subtypes and thus revealed
psoriasis risk genes shared by the majority of phenotypes.
However, when using carefully phenotyped psoriasis cohorts,
genetic exploration will likely reveal new risk variants.
Stratiﬁcation of phenotypes can be performed in many
ways: age of disease onset, severity, presence of
comorbidities, and family history just to mention a few. In
the current study, we have compared the association of
known genetic risk factors focusing on the IL-23 and NF-κB
pathways between two polarized cohorts of psoriasis indivi-
duals, those with consistently mild psoriasis who have not
required systemic therapy for at least 6–14 years disease
course but been treated only topically or not at all, and severe
psoriasis requiring systemic therapy. Our study reveals that
association of these susceptibility genes is restricted to the
severe psoriasis skin phenotype.
RESULTS
Genetic association with IL23R, NFKB1, IL21, IL12B, NFKBIL1,
and IL23A was conﬁned to psoriasis cases with severe skin
phenotype
The samples analyzed are shown in Table 1 where basic
indicators such as age at onset, disease duration, BMI, and
psoriasis nail involvement are presented. PASI values are
calculated after 6–14 years disease in the mild cohort and at
inclusion in the severe cohort. Only few patients were without
therapy or with short wash-out after previous treatments when
included in the latter registry. Still, the data show signiﬁcant
differences between the cohorts.
Genotypes and minor allele frequencies of the examined
gene variants are shown in Table 2. In addition to HLA-C*06,
we found strong association with TRAF3IP2 (rs33980500-T),
TNFAIP3 (rs610604-C), STAT3 (rs9912773-G), TNF
(rs1800629-G), IL23A (rs2066808-A), and IL12B (rs285394-G)
in all psoriasis subjects (Table 2), with all P-values remaining
signiﬁcant after correction for multiple testing (Po0.05). We
also found signiﬁcant association with IL12B (rs10045431-A),
NFKBIL1 (rs2255798-G), as well as for IL13 (rs20541-C), TNIP1
(rs3762999-G), TYK2 (rs12720356-T), and IL12RB1 (rs401502-
C), for all psoriasis subjects (Table 2) but with only association
with TYK2 remaining signiﬁcant after multiple testing
(Po0.05). Intriguingly, when analyzing severe versus control
and mild versus control, the association for IL12B (rs10045431-
A), NFKBIL1 (rs2255798-G), and IL23A (rs2066808-A) dis-
appeared for the mild clinical phenotype and increased or
remained the same in the severe phenotype (Table 3). When
analyzing severe versus mild phenotypes in a case–case study,
the common allele for IL23R (rs7530511), IL21 (rs2221903),
IL12B (rs3212227), and IL23A (rs2066808) showed association
with the severe phenotype, whereas for IL23R (rs2201841),
NFKB1 (rs2293970), IL12B (rs10045431), and NFKBIL1
(rs2255798) the minor allele showed association with risk to
the severe phenotype (Figure 1 and Table 3). Both SNPs in
IL23R (rs7530511 and rs2201841) as well as NFKBIL1
(rs2255798) and IL23A (rs2066808) remained signiﬁcant
after multiple testing (Po0.05). No association for REL and
NFKBIA was observed for either phenotype. We observed no
deviation from Hardy–Weinberg equilibrium for any of
the markers (P40.05), and duplicates did not reveal any
genotyping errors.
Haplotype analysis for the IL23R and IL12B genes signiﬁcantly
increased association with psoriasis cases with severe disease
Haplotype association, with at least one risk allele present for
both SNPs in the IL23R gene, increased the association odds
ratio (OR) to 1.55 (P= 0.003, 95% conﬁdence interval (CI)
Table 1. Characteristics of participants
All cases Severe Mild Controls
(N= 1,411) (N= 715) (N= 696) (N=1,529)
Women (%) 630 (47) 274 (38) 407 (58) 806 (53)
Mean age at onset
(min–max)
33.8 30.0 (1–69) 37.5 (1–84)
Disease duration
(min–max)
26 (3–70) 12 (6–14)
PASI (min–max) 13 (1–37) 1.6 (0–9)
Nail involvment (%) 272 (37) 87 (13)
BMI (min–max) 28 (16–45) 25 (15–42)
HLA-C*06 positive
Freq
0.22 0.20 0.23 0.07
Abbreviations: BMI, body mass index; PASI, psoriasis area severity index.
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1.26–1.91) (Supplementary Table S1 online) in the severe
disease cohort. Two IL12B haplotypes were associated
with severe psoriasis (Supplementary Table S1 online). The
strongest association was seen for the haplotype with at least
one risk allele present for all three SNPs in the IL12B gene
(P= 9× 10-6, OR 1.64; 95% CI: 1.30–2.07). Interestingly, the
OR increased to 2.19 (P= 0.005, 95% CI 1.40–3.41), with two
risk alleles present for all variations of the IL12B gene
(Supplementary Table S1 online). In addition, we performed
a χ2-test for trend, which for the allelic haplotype in IL23R
showed χ2=16.07 (Po0.00006), for the allelic haplotype in
IL12B showed χ2=22.58 (Po0.00001), and for the genotypic
haplotype in IL12B showed χ2=15.51 (Po0.00008)
(Supplementary Table S1 online). All P-values remained
signiﬁcant after multiple testing (Po0.05).
Interaction between genes within and between the IL-23 and
NF-κB pathways
To analyze interaction, we selected ten genes, IL23R, NFKB1,
TNIP1, IL12B, HLA-C, NFKBIL1, TNF, TRAF3IP2, IL23A, and
STAT3, to be analyzed against all other sixteen genes. In the
severe psoriasis phenotype, we observed biological interac-
tion on the additive scale between genes in the two different
pathways: TNFAIP3 and NFKBIL1 (APp 0.02, AP 0.297
(0.049–0.545), P= 5× 10−7, OR 2.02; 95% CI: 1.54–2.66)
(Figure 2a and Supplementary Table S2 online) and TNIP1
and IL23R (APp 0.04, AP 0.275 (0.007–0.543), P= 1× 10−6,
OR 2.01; 95% CI: 1.51–2.66) (Supplementary Table S2
online). The most signiﬁcant interaction was found between
TNIP1 and NFKBIL1 (APp 0.000001, AP 0.503 (0.301–0.705),
P= 1× 10− 8, OR 2.58; 95% CI: 1.86–3.58) (Figure 2b and
Supplementary Table S2 online). In the severe psoriasis
phenotype, we also observed an interaction on the additive
scale between the HLA-C risk allele and ﬁve other genes risk
alleles: IL23R (Figure 2c), NFKB1 (Figure 2d), TNIP1, IL12B,
and IL23A (Supplementary Table S2 online). No interaction
was observed in the mild disease group. The two most
signiﬁcantly associated interactions remained signiﬁcant after
correction: TNIP1 and NFKBIL1 as well as HLA-C and NFKB1
(Po0.05).
Table 2. Marker information and association analyzed in all subjects
All subjects
Gene Chr SNP position Allele2 MAF3 Function Pathway6 P-value OR4 (95% CI)
IL23R 1 rs7530511 67685387 C1/T 0.16 p.Leu310Pro IL23 0.05 0.87 (0.75–1.00)
IL23R 1 rs2201841 67694202 A/G a 0.29 Intron IL23 0.10 1.10 (0.98–1.23)
REL 2 rs702873 61081542 C1/T 0.43 Intragenic IL23/NFkB 0.06 0.90 (0.81–1.00)
NFKB1 4 rs2293970 103487982 A/T1 0.05 Intron IL23/NFkB 0.33 1.12 (0.90–1.39)
IL21 4 rs2221903 123538912 A1/G 0.37 Intron IL23 0.13 0.92 (0.83–1.03)
IL13 5 rs20541 131995964 C1/T 0.23 p.Pro144Leu 0.03 0.87 (0.77–0.99)
TNIP1 5 rs3762999 150469426 G1/A 0.48 Intragenetic IL23/NFkB 0.006 0.87 (0.78–0.96)
IL12B 5 rs3212227 158742950 A1/C 0.17 3’ UTR IL23 0.22 0.92 (0.80–1.05)
IL12B 5 rs2853694 158749088 G1/T 0.49 Intron IL23 3× 10-6 0.78 (0.71–0.87)
IL12B 5 rs10045431 158814533 C/A1 0.28 57 kb upstream IL23 0.02 1.15 (1.02–1.29)
HLA-C 6 HLA-C*065 31311986 N/P1 0.07 HLA-C*06 NFKB 3× 10-55 4.02 (3.38–4.79)
NFKBIL1 6 rs2255798 31521302 C/G1 0.14 Intron NFkB 0.04 1.17 (1.01–1.35)
TNF 6 rs1800629 31543031 G1/A 0.19 Intron IL23/NFKB 8× 10-8 0.68 (0.59–0.78)
TRAF3IP2 6 rs33980500 111913262 C/T1 0.06 p.Asp10Asn NFkB 8× 10-7 1.61 (1.33–1.95]
TNFAIP3 6 rs610604 138199417 A/C1 0.32 Intron NFkB 0.0001 1.24 (1.11–1.38)
IL23A 12 rs2066808 56737973 A1/G 0.08 Intron IL23 6× 10-6 0.60 (0.49–0.75)
NFKBIA 14 rs1957106 35873770 G1/A 0.31 p.Asp27Asp IL23/NFkB 0.30 0.94 (0.83–1.06)
STAT3 17 rs9912773 40510534 C/G1 0.24 Intron IL23 0.0001 1.26 (1.12–1.42)
TYK2 19 rs12720356 10469975 T1/G 0.10 p.Ile684Ser IL23 0.003 0.76 (0.63–0.91)
IL12RB1 19 rs401502 111913262 C1/G 0.33 p.Gly378Arg IL23 0.02 0.88 (0.79–0.98)
Abbreviations: CI, conﬁdence interval; OR, odds ratio; MAF, minor allele frequency; SNP, single-nucleotide protein. P-values in bold are signiﬁcant after
correction for multiple testing using the adjust mode as implemented in PLINK v1.07 (Purcell et al., 2007) (Po0.05).
1Risk allele.
2Major/Minor allele.
3data from our controls.
4Contemplates OR for the minor allele.
5Typing according to Nikamo and Ståhle (2012).
6According to GeneCards (http://www.genecards.org/) and PathCardalpha (http://pathcards.genecards.org/).
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DISCUSSION
This study describes association with genes in the IL-23 and
NF-κB pathways in carefully characterized Swedish psoriasis
cohorts stratiﬁed by severity of the skin phenotype. Several
studies have previously highlighted the importance of genes
and haplotypes in both the IL-23 and NF-κB pathways in
psoriasis (Nair et al., 2009; Safrany et al., 2011; Safrany et al.,
2013) as well as in many other immune-mediated diseases:
Table 3. Case–case study reveals distinct genetic proﬁles in severe versus mild psoriasis
Severe versus controls Mild versus controls Severe versus mild
Gene Chr SNP FU FA P-value OR1 (95% CI) FA P-value OR1 (95% CI) P-value OR1 (95% CI)
IL23R 1 rs7530511 0.16 0.12 0.0007 0.72 (0.60–0.87) 0.16 0.86 1.02 (0.88–1.21) 0.002 0.71 (0.57–0.88)
IL23R 1 rs2201841 0.29 0.34 0.004 1.22 (1.07–1.40) 0.29 0.72 0.99 (0.86–1.14) 0.006 1.26 (1.07–1.48)
REL 2 rs702873 0.43 0.40 0.06 0.88 (0.77–1.01) 0.41 0.68 0.92 (0.81–1.05) 0.76 0.98 (0.84–1.14)
NFKB1 4 rs2293970 0.05 0.07 0.04 1.31 (1.01–1.71) 0.05 0.35 0.93 (0.70–1.24) 0.04 1.40 (1.01–1.92)
IL21 4 rs2221903 0.37 0.33 0.01 0.85 (0.74–0.97) 0.37 0.70 1.00 (0.88–1.14) 0.04 0.85 (0.73–0.99)
IL13 5 rs20541 0.23 0.19 0.006 0.80 (0.69–0.94) 0.22 0.92 0.95 (0.81–1.10) 0.06 0.83 (0.69–1.01)
TNIP1 5 rs3762999 0.48 0.43 0.01 0.84 (0.74–0.97) 0.45 0.05 0.89 (0.79–1.02) 0.31 0.93 (0.80–1.07)
IL12B 5 rs3212227 0.17 0.14 0.02 0.80 (0.67–0.96) 0.17 0.71 1.03 (0.87–1.23) 0.04 0.80 (0.65–0.99)
IL12B 5 rs2853694 0.49 0.41 4× 10-6 0.74 (0.65–0.84) 0.44 0.003 0.82 (0.73–0.94) 0.25 0.91 (0.79–1.06)
IL12B 5 rs10045431 0.28 0.33 0.002 1.25 (1.09–1.44) 0.29 0.34 1.05 (0.91–1.22) 0.04 1.19 (1.01–1.40)
HLA-C 6 HLA-C*062 0.07 0.20 5× 10-36 3.61 (2.95–4.41) 0.23 2× 10-40 4.32 (3.53–5.28) 0.29 0.90 (0.74–1.10)
NFKBIL1 6 rs2255798 0.14 0.17 0.0004 1.37 (1.15–1.64) 0.13 0.40 0.98 (0.82–1.18) 0.002 1.39 (1.12–1.72)
TNF 6 rs1800629 0.19 0.14 1× 10−5 0.70 (0.59–0.84) 0.13 1× 10-5 0.65 (0.54–0.78) 0.34 1.12 (0.89–1.39)
TRAF3IP2 6 rs33980500 0.06 0.11 8× 10-7 1.75 (1.40–2.19) 0.09 0.04 1.45 (1.15–1.83) 0.25 1.16 (0.90–1.49)
TNFAIP3 6 rs610604 0.32 0.37 0.002 1.23 (1.08–1.40) 0.37 0.003 1.25 (1.09–1.42) 0.76 0.98 (0.83–1.14)
IL23A 12 rs2066808 0.08 0.04 2× 10-7 0.44 (0.32–0.60) 0.06 0.05 0.78 (0.61–1.01) 0.0005 0.53 (0.37–0.76)
NFKBIA 14 rs1957106 0.31 0.29 0.15 0.89 (0.76–1.04) 0.31 0.87 0.97 (0.84–1.13) 0.23 0.90 (0.75–1.07)
STAT3 17 rs9912773 0.24 0.28 0.0009 1.28 (1.11–1.49) 0.28 0.004 1.25 (1.08–1.44) 0.66 1.04 (0.88–1.23)
TYK2 19 rs12720356 0.10 0.07 0.002 0.69 (0.54–0.87) 0.08 0.05 0.83 (0.67–1.04) 0.19 0.83 (0.63–1.10)
IL12RB1 19 rs401502 0.33 0.31 0.23 0.92 (0.80–1.05) 0.29 0.06 0.85 (0.74–0.97) 0.56 1.05 (0.89–1.25)
Abbreviations: CI, conﬁdence interval; FA, allele frequency affected; FU, allele frequency unaffected; OR, odds ratio; SNP, single-nucleotide protein. P-values
in bold are signiﬁcant after correction for multiple testing considering stratiﬁcation into two cohorts using the Sidák correction (Sidák, 1967) (Po0.05).
1Contemplates OR for the minor allele.
2Typing according to Nikamo and Ståhle (2012).
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Figure 1. Association of markers analyzed in psoriasis subjects. Stratiﬁcation of psoriasis patients reveals association in the severe phenotype. Odds ratios for
case–control study are shown, and a case–case study exposes distinct genetic proﬁles in severe versus mild psoriasis. Three of the most signiﬁcantly associated
genes remained signiﬁcant after correction: IL23R, IL23A, and NFKBIL1 (Po0.05). *Po0.05, **Po0.01, and ***Po0.001.
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PsA (Cargill et al., 2007; Capon et al., 2007; Liu et al., 2008;
Nair et al., 2010; Franke et al., 2010; Strange et al., 2010;
Bowes et al., 2011; Wang et al., 2012; Di Meglio et al., 2013;
Popa et al., 2013; Eiris et al., 2014), Crohn’s disease (Chua
et al., 2012; Dinu et al., 2012; Jung et al., 2012), inﬂammatory
bowel disease (Duerr et al., 2006; Safrany et al., 2013),
ankylosing spondylitis (Safrany et al., 2009), celiac disease,
and multiple sclerosis (Nunez et al., 2008).
The present study revealed that eight SNPs in six of the
studied genes associate with psoriasis with a severe pheno-
type, whereas no association was found in patients with a
consistent mild phenotype (Figure 1). There are several
measures to assess clinical severity in psoriasis skin disease
such as, PASI, body surface area, psoriasis global assessment,
and patient’s global assessment. There is no ultimate measure
but the most commonly used is PASI, which works reasonably
well at a given time point. However, our aim was to study long-
term disease course, and we have access to a unique group of
patients with long-term follow-up, thus ensuring a conﬁdent
phenotype over time. In this study, the deﬁnition of mild
psoriasis was patients who had not received, nor been eligible
for systemic therapy up to 14 years following onset. Severe
psoriasis was deﬁned as treatment with systemic therapy
indicated by psoriasis skin disease. In a substantial proportion
of patients with severe psoriasis, the baseline PASI scores were
not available. Therefore, deﬁning severity based on treatment is
in our opinion functionally relevant. Only three dermatologists
in close collaboration in the same department have treated
these patients; hence, we feel conﬁdent that the assessment is
harmonized. The aim was to study speciﬁcally psoriasis skin
disease, and to optimize the stratiﬁcation we have not included
assessment of PsA. The psoriasis population primarily treated in
dermatology differs from the PsA population in rheumatology;
thus, our patients do not represent the complete PsA
phenotype.
HLA-C*06 is without question the strongest associated gene
in psoriasis. Interestingly, this still holds true when stratiﬁed by
severity and HLA-C*06 was equally associated in the severe
and mild cohorts with no statistical difference between the
groups.
Herein we show that association with ﬁve SNPs within the
IL23R, IL23A, and IL12B genes is conﬁned to the severe
psoriasis phenotype. IL-23 has a crucial role in the develop-
ment of pathogenic Th17 cells and is critically involved in
autoimmune inﬂammatory diseases (Aggarwal et al., 2003;
Bettelli et al., 2006). Knockout mice deﬁcient for IL-23, for
either p40 or p19, or for either subunit of the IL-23 receptor
develop less severe symptoms of multiple sclerosis and
inﬂammatory bowel disease emphasizing the general impor-
tance of IL-23 in inﬂammation (Langowski et al., 2006; Kikly
et al., 2006), and therapy blocking the p40 subunit shared
between IL-23 and IL-12 shows impressive clinical efﬁcacy in
psoriasis (Leonardi et al., 2008).
NFKBIL1 also showed association conﬁned to the severe
phenotype of psoriasis. NFKBIL1 is important in the regulation
of the NF-κB pathway and has been implicated in the
pathogenesis of rheumatoid arthritis, ulcerative colitis (asso-
ciation with the severe type), and systemic lupus erythema-
tosus (De La Concha et al., 2000; Greetham et al., 2007; Cen
et al., 2013) but has not previously been reported in psoriasis.
In our material, there was no association with NFKB1 in the
whole material, but a signiﬁcant difference between the
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groups was detected when stratifying for severity. This is in
line with published data reporting association with NFKB1 in
severe psoriasis with PASI 420 (Li et al., 2008). Similarly,
there was no association with IL21 in the combined cohorts,
but after stratiﬁcation the severe group showed association,
indicating an effect on disease severity from IL-21. IL-21 is
produced by activated CD4+T cells (among others) and has an
important regulatory role in the immune system. Caruso et al.,
2009b have shown a role for IL-21 in promoting epidermal
hyperplasia and expanding pathogenic Th-cell responses in
psoriasis (Caruso et al., 2009b). The SNP rs12720356-T allele
in TYK2 showed association in the whole psoriasis group, but
after stratiﬁcation the association remained only in the severe
group and disappeared in the mild group. Although we
cannot show a signiﬁcant difference between the groups, this
is still intriguing as TYK2 is part of the IL-23 pathway, which
seems preferentially involved in the severe psoriasis pheno-
type, and inhibition of Tyk2 kinase activity led to signiﬁcantly
reduced IL-23-induced skin inﬂammation and may be an
effective therapeutic strategy for the treatment of psoriasis
(Liang et al., 2013; Ishizaki et al., 2014).
For the entire psoriasis cohort, there were signiﬁcant
associations for STAT3, TNF, TNFAIP3, and TRAF3IP2 but
with no signiﬁcant difference when stratiﬁed by severity,
indicating their overall involvement.
Signiﬁcant research is devoted to the detection and
investigation of interaction between genes. For complex
traits, gene interaction has become a hot topic. Thus, in the
presence of interaction, where the effect of one locus is
altered or masked by the effect of another locus, the power to
detect the ﬁrst locus may be reduced. Even though HLA-C*06
associates equally strong in both cohorts, interaction between
HLA-C*06 and risk alleles in IL23R, NFKB1, TNIP1, IL12B,
and IL23A (Supplementary Table S2 online) was restricted to
the severe phenotype. TNIP1 also interacted with IL23A and
NFKBIL1, whereas NFKBIL1 also interacted with STAT3 only
in the severe cohort.
Finally, in a haplotype analysis of the severe phenotype, an
even stronger association could be shown for IL23R and IL12B
when considering more than one risk allele (Supplementary
Table S1 online).
Taken together, the data presented here show the
importance of careful phenotyping and long-term follow-up
of clinical materials. This may be cumbersome and difﬁcult to
achieve but is likely rewarding in understanding the genetic
complexity and will pave the way for effective personalized
medicine. In addition, it is important to study the combina-
tions of SNPs, and not only the individual SNPs, as some
polymorphisms tend to act only in speciﬁc blocks and may be
overlooked otherwise.
MATERIALS AND METHODS
Samples
The analyses were carried out on 1,411 psoriasis patients of
Caucasian ethnicity (781 males and 630 females; average age of
onset 33.8 years; range 1–84 years) and 1,529 ethnically matched
controls (723 males and 806 females; age not known) (Table 1).
All patients included in the study were examined and the diagnosis of
psoriasis veriﬁed by only three different dermatologists at the
department of Dermatology, Karolinska University Hospital, Stock-
holm, Sweden. For inclusion, patients needed to present with at least
one typical psoriasis lesion at the time for examination. Scalp
involvement only was not regarded as diagnostic. Patients who had
needed only topical treatment during the 6- to 10-year follow-up
period were diagnosed with mild psoriasis, whereas patients who
needed systemic treatment were diagnosed with severe psoriasis. The
severe group had a disease duration up to 26 years and was followed
for a minimum 6 years. The study was approved by the Regional
Committee of Ethics and performed according to the Declaration of
Helsinki Principles. Healthy controls were recruited at the dermatol-
ogy (n= 507) clinic at the Karolinska University Hospital and as
blood donors at the Karolinska University hospital (n= 1,022).
Patients and controls provided written informed consent, and, for
children below 18 years of age, parental written consent was
obtained. Only cases and controls of Caucasian origin based on
ethnicity SNP genotyping were included (Giardina et al., 2008).
Genotyping
Peripheral blood samples were collected and genomic DNA extracted
by standard procedures. The genes included in our present study were
genes previously reported to be associated with psoriasis at
ImmunoBase (http://www.immunobase.org/) and that were conﬁrmed
to be involved in the IL-23 and NF-κB signaling pathway according to
GeneCards (http://www.genecards.org/) and PathCardalpha (http://
pathcards.genecards.org/). The selection of SNPs included in our
study was based on published data, and priority was given to SNPs
previously reported to be associated with psoriasis. All SNPs were
genotyped on the ABI PRISM 7900HT Fast Real-Time PCR System
Instrument by using allele speciﬁc Taqman MGB probes labeled with
ﬂuorescent dyes FAM and VIC (Applied Biosystems, Foster City, CA,
USA), according to the manufacturer’s protocols. Allelic discrimination
was made with the ABI PRISM 7900HT SDS and the SDS 2.2.1
program (Applied Biosystems). Genotyping success rates exceeded
99% for all SNPs in the total sample set. Ten percent of the samples
were run as duplicates to check for genotyping errors. HLA-C*06:02
typing was carried out as previously described by Nikamo et.al.
(Nikamo and Ståhle, 2012).
Statistical analysis
Case–control analysis was performed to test association with psoriasis
comparing with population controls. Case–case analysis was used to
compare severe and mild phenotypes. Both case–control and the
case–case analyses were tested for allele frequency differences for all
SNPs using logistic regression with gender and age as covariates.
Associations between genetic markers and disease status were
analyzed using the PLINK v1.07 (Purcell et al., 2007). The potential
interaction between genes was examined by calculation of departure
from additivity of effects and evaluated by calculating attributable
proportion (AP) due to interaction, as suggested by Rothman, together
with a 95% CI, using the R program v 2.15.0 with GLM (http://www.
r-project.org/). Haplotypes were analyzed using the R program v 2.15.0
with GLM (http://www.r-project.org/). For the Trend test, we used χ2
for trend by the extended Mantel-Haenszel, as implemented in
StatCalc, Epi info 7.1.3.0 (http://wwwn.cdc.gov/epiinfo/7/index.htm).
For both haplotype and Trend test score zero was used for the
reference haplotype in which no risk alleles were present; increasing
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score numbers were then used for increasing number of risk alleles,
considering both hetero- and homozygotes. Hardy–Weinberg
equilibrium was evaluated for each SNP using a χ2-test.
We have highlighted P-values that would remain signiﬁcant after
correction for multiple testing using the adjust mode as implemented
in PLINK v1.07 (Purcell et al., 2007) (Table 2). In data presented in
Table 3, we have adjusted for stratiﬁcation into two cohorts; mild and
severe, using the Sidák correction (Sidák, 1967), where P-values are
adjusted using simple functions of the number of tested hypotheses.
For haplotype analysis Sidák correction was also used to adjust for
multiple testing, two comparisons for IL23R and ﬁve comparisons for
IL12B. Sidák correction was also used to adjust for multiple testing in
the interaction analysis, where 10 genes were selected and compared
against all other sixteen genes, thus resulting in 160 tests.
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